We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
WPD Pharmaceuticals has entered into a development agreement with CNS Pharmaceuticals for the development of several preclinical drug candidates including WP1122.
WPD Pharmaceuticals has provided an update that through its license partner, CNS Pharmaceuticals, it received positive feedback from the U.S. Food and Drug Administration (FDA) for its Pre-IND ...
Pursuant to the completion of the Transaction, the Company issued 67,000,000 common shares to the WPD Securityholders in exchange for 100% of the issued and outstanding securities of WPD. Upon completion of the Transaction, WPD has become a wholly-owned s